Supernus Pharmaceuticals Inc (NASDAQ: SUPN) stock suffered a major decline of -15.7% on 2/19/25. The shares closed at $33.52. Moreover, this decline was accompanied by exceptionally high trading volume at 536% of normal. The stock has declined -11.6% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Supernus Pharmaceuticals has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Supernus Pharmaceuticals has a slightly negative Appreciation Score of 38 but a good Power Rating of 82, and the High Neutral Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment